Oncologists Underestimate Patient Use of Complementary Medicine
TUESDAY, June 1, 2021 (HealthDay News) – Oncologists may substantially underestimate how many...
Read More
Dissemination (Meeting Coverage)
ASCO 2021: How does high intensity interval training impact advanced NSCLC?
Patients with advanced non-small cell lung cancer (NSCLC) experience fatigue and physical deconditioning, altering their quality of life (QoL). However, the safety and feasibility of high intensity exercise in advanced NSCLC has...
Read More
Targeting CNS cells Key to Abrogate MS Progression
Prof. Tony Traboulsee talks to Physician’s Weekly about his study of tolebrutinib Presented at the...
Read MoreAAN 2021: Significant Discrepancy Found in General vs Neuroradiologists MRI Reporting of MS
Management of patients with multiple sclerosis (MS) in the era of disease modifying therapies (DMT) relies heavily on magnetic resonance imaging (MRI) and the support of dedicated multidisciplinary teams (MDTs). While decisions...
Read MoreAAN 2021: Identifying distinct cognitive phenotypes in multiple sclerosis
Cognitive impairment is a common and disabling feature of multiple sclerosis (MS), but a precise characterization of cognitive phenotypes in MS patients is still lacking. This study identified five cognitive phenotypes:...
Read MoreAAN 2021: Dual Tasking In Patients With MS
Patients with MS may have difficulty performing double task (DT) while walking or causing interference. More research is needed in order to define the role of disability degree in the severity of the interference produced in the...
Read More
ASCO GU 2021: Superior clinical outcomes and quality of life with nivolumab plus cabozantinib in renal cell cancer
In CheckMate 9ER, patients with renal cell cancer (RCC) treated with nivolumab plus cabozantinib...
Read MoreSABCS 2020: First Immunotherapy Combo Well-Tolerated
In an interim analysis of the first immunotherapy combination phase 1b trial with trastuzumab deruxtecan, safety results showed nivolumab with trastuzumab deruxtecan was well tolerated in patients with HER2-positive or HER2-low...
Read More